Low levels of minimal residual disease after induction chemotherapy for BCR-ABL1-negative acute lymphoblastic leukaemia in adults are clinically relevant.
Cyril SalekFrantišek FolberEva FroňkováPavla PecherkováHana JelínkováŠtěpán HrabovskýJan M HoráčekPetr CetkovskýJiří MayerJan TrkaMichael Doubeknull nullPublished in: British journal of haematology (2021)
The aim of the present study was to evaluate the significance of low-level minimal/measurable residual disease (MRD) during early consolidation treatment in adult BCR-ABL1-negative acute lymphoblastic leukaemia. The MRD load was monitored by immunoglobulin/T-cell receptor rearrangements and assessed as negative [complete MRD response (CMR)], positive non-quantifiable (MRDnq) and positive quantifiable (MRDq). MRDnq before the first and second consolidation blocks had a comparable negative effect on survival as MRDq. The 5-year overall survival for CMR, MRDnq and MRDq at week 11 was 74·0%, 42·3% and 35·0% respectively. No central nervous system infiltration and MRD at week 11 were independent prognostic factors for survival on multivariate analysis (hazard ratios 0·32 and 2·25).
Keyphrases
- tyrosine kinase
- prognostic factors
- chronic myeloid leukemia
- liver failure
- acute lymphoblastic leukemia
- respiratory failure
- free survival
- drug induced
- aortic dissection
- squamous cell carcinoma
- clinical trial
- radiation therapy
- young adults
- hepatitis b virus
- combination therapy
- binding protein
- replacement therapy
- double blind